RTW Investments’s Cytokinetics CYTK Stock Holding History

RTW Investments’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$244M	Buy	2,862,003 +140,845	+5%	+$10.1M	2.08%	16
2026 Q1	$179M	Hold	2,721,158	–	–	1.78%	18
2025 Q4	$173M	Hold	2,721,158	–	–	1.73%	18
2025 Q3	$150M	Hold	2,721,158	–	–	1.84%	17
2025 Q2	$89.9M	Hold	2,721,158	–	–	1.28%	25
2025 Q1	$109M	Hold	2,721,158	–	–	1.67%	22
2024 Q4	$128M	Hold	2,721,158	–	–	1.94%	20
2024 Q3	$144M	Hold	2,721,158	–	–	2.08%	21
2024 Q2	$147M	Buy	2,721,158 +196,078	+8%	+$11.8M	2.28%	17
2024 Q1	$177M	Hold	2,525,080	–	–	2.61%	13
2023 Q4	$211M	Sell	2,525,080 -49,118	-2%	-$1.78M	3.29%	10
2023 Q3	$75.8M	Hold	2,574,198	–	–	1.6%	20
2023 Q2	$84M	Hold	2,574,198	–	–	1.6%	21
2023 Q1	$90.6M	Hold	2,574,198	–	–	1.89%	22
2022 Q4	$118M	Hold	2,574,198	–	–	2.41%	16
2022 Q3	$125M	Buy	2,574,198 +13,016	+0.5%	+$626K	2.88%	12
2022 Q2	$101M	Hold	2,561,182	–	–	2.6%	11
2022 Q1	$94.3M	Hold	2,561,182	–	–	1.95%	21
2021 Q4	$117M	Buy	2,561,182 +561,182	+28%	+$21.7M	1.7%	17
2021 Q3	$71.5M	Hold	2,000,000	–	–	1.08%	30
2021 Q2	$39.6M	Hold	2,000,000	–	–	0.6%	43
2021 Q1	$46.5M	Hold	2,000,000	–	–	0.73%	42
2020 Q4	$41.3M	Hold	2,000,000	–	–	0.69%	38
2020 Q3	$40.7M	Buy	+2,000,000	New	+$46.8M	0.98%	31

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RTW Investments's CYTK Position: Q2 2026 in Review

RTW Investments increased its Cytokinetics (CYTK) stake by 5.2% in Q2 2026, buying an estimated $10.1M and bringing the position to 2,862,003 shares worth $244M. The position accounts for 2.08% of the portfolio, ranked #16.

RTW Investments first reported a position in CYTK in Q3 2020 and has held it in 24 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

RTW Investments held 2,862,003 shares of Cytokinetics worth $244M as of Q2 2026.
RTW Investments bought 140,845 Cytokinetics shares in Q2 2026, an estimated $10.1M.
Cytokinetics made up 2.08% of RTW Investments's portfolio in Q2 2026, its #16 holding.
RTW Investments first reported a position in Cytokinetics in Q3 2020 and has held it in 24 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on RTW Investments's 13F filing for Q2 2026, filed 14 Aug 2026.